Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine

• 발행기관: 대한신경정신의학회
• 저자명: YoungMin Park
• 간행물 정보: 『Psychiatry Investigation』제9권 제4호, 422~424쪽, 전체 3쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2012.12.31

영문 초록

I report here an elderly woman receiving perphenazine together with terbinafine. After 1 week of terbinafine treatment she experienced extrapyramidal symptoms and, in particular, akathisia. Her symptoms did not disappear for 6 weeks, and so at 2 weeks prior to this most recent admission she had stopped taking terbinafine. However, these symptoms persisted for 3 weeks after discontinuing terbinafine. It is well known that terbinafine inhibits CYP2D6 and that perphenazine is metabolized mainly by CYP2D6. Thus, when terbinafine and perphenazine are coadministrated, the subsequent increase in the concentration of perphenazine may induce extrapyramidal symptoms. Thus, terbinafine therapy may be associated with the induction and persistence of extrapyramidal symptoms, including akathisia. This case report emphasizes the importance of monitoring drug-drug interactions in patients undergoing terbinafine and perphenazine therapy.

목차

INTRODUCTION

CASE

DISCUSSION

ACKNOWLEDGEMENTS

REFERENCES

키워드

Terbinafine Perphenazine Drug-drug interaction Akathisia Extrapyramidal symptoms